NASDAQ:KYTX Kyverna Therapeutics Q3 2026 Earnings Date & Estimates $5.77 -0.44 (-7.09%) Closing price 10/13/2026 04:00 PM EasternExtended Trading$5.77 0.00 (0.00%) As of 08:40 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Kyverna Therapeutics is estimated to report Q3 2026 earnings on Wednesday, November 11, 2026. The conference call is scheduled for November 12, 2026 at 4:00 PM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 11, 2026Conference Call DateNovember 12, 2026Conference Call4:00 PM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Kyverna Therapeutics in Q3 2026Kyverna Therapeutics is expected to post earnings of -$0.68 per share. In the same quarter a year earlier Kyverna Therapeutics reported -$0.85 per share. Kyverna Therapeutics last reported on August 11, 2026, posting -$0.63 per share and beating the -$0.6783 consensus estimate. Kyverna Therapeutics has beaten the consensus EPS estimate in 6 of its last 8 quarters.Consensus EstimatesConsensus EPS-$0.68Prior-Year EPS-$0.85Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$0.63 (Beat by +$0.0483)EPS Beat Rate6 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report Kyverna Therapeutics Q3 2026 Earnings FAQ When does Kyverna Therapeutics report Q3 2026 earnings? Kyverna Therapeutics (NASDAQ:KYTX) is estimated to report Q3 2026 earnings on Wednesday, November 11, 2026. This date is estimated from past reporting schedules and may change once the company confirms it. What time is Kyverna Therapeutics' Q3 2026 earnings call? Kyverna Therapeutics' Q3 2026 earnings conference call is scheduled for Thursday, November 12, 2026 at 4:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Kyverna Therapeutics? Analysts expect Kyverna Therapeutics to post earnings of -$0.68 per share for Q3 2026. Kyverna Therapeutics Earnings HeadlinesKyverna Therapeutics to Present Positive Data in Stiff Person Syndrome and Progressive Multiple Sclerosis at MSToronto2026October 7, 2026 | globenewswire.comKyverna Therapeutics, Inc. (NASDAQ:KYTX) Stock Has Consensus Price Target of $29.00 According to AnalystsOctober 3, 2026 | americanbankingnews.comHow one AI fund pays investors every ThursdayOne small fund tied to artificial intelligence stocks delivered $1,051 in a single month, not through selling shares or trading options, but simply by holding the fund and letting it pay out cash every Thursday. That works out to a 34% annualized distribution rate, even though the underlying AI stocks pay no dividends themselves. Tim Plaehn, Chief Income Strategist at Investors Alley, breaks down exactly how the fund generates these weekly payouts.October 14 at 1:00 AM | Investors Alley (Ad)HEALTH ROUNDS-Appendix removal linked with lower colon cancer risk in studyOctober 2, 2026 | marketscreener.comMAnalysts Offer Insights on Healthcare Companies: Aethlon Medical (AEMD) and Kyverna Therapeutics, Inc. (KYTX)September 25, 2026 | theglobeandmail.comKYTX stock reverses gains after one-year cell therapy trial data but CEO says disease burden justifies a premium priceSeptember 25, 2026 | msn.comSee More Kyverna Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Kyverna Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Kyverna Therapeutics and other key companies, straight to your email. Email Address About Kyverna TherapeuticsKyverna Therapeutics (NASDAQ:KYTX) is a clinical-stage biotechnology company focused on developing cell therapies for severe autoimmune diseases. The company is working to apply chimeric antigen receptor T-cell (CAR T) technology, traditionally used in certain cancers, to conditions in which abnormal B cells contribute to disease. Kyverna’s lead product candidate, KYV-101, is an autologous, fully human CD19-directed CAR T-cell therapy designed to eliminate B cells and potentially reset dysfunctional immune responses. The company is evaluating KYV-101 in several autoimmune indications, including systemic lupus erythematosus, lupus nephritis, systemic sclerosis, idiopathic inflammatory myopathies, multiple sclerosis and myasthenia gravis. Founded in 2018 and headquartered in Emeryville, California, Kyverna is advancing its therapies through clinical development and collaborations with academic and medical research centers. The company does not currently have an approved commercial product and is primarily focused on generating clinical evidence for its autoimmune cell therapy platform.View Kyverna Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles A Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?Tax Credit Turmoil: Why Enphase and SolarEdge Face a Tough RoadSurgical Precision, Sustainable Returns: Johnson & Johnson Secures Its Cash Flow RunwayJPMorgan Earnings Miss Estimates But Reveal Broad-Based StrengthAmazon's $220 Billion AI Bet Is Getting Bigger—Can Earnings Justify the Spending?A Silent Winner: Texas Instruments Anchors the AI SupercycleDelta's Guidance Cut Could Spell Trouble for the Airline Industry Upcoming Earnings Interactive Brokers Group (10/15/2026)Marsh & McLennan Companies (10/15/2026)The PNC Financial Services Group (10/15/2026)Charles Schwab (10/15/2026)U.S. Bancorp (10/15/2026)Prologis (10/15/2026)Taiwan Semiconductor Manufacturing (10/15/2026)Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
